Form 8-K - Current report:
SEC Accession No. 0001193125-24-209907
Filing Date
2024-08-29
Accepted
2024-08-29 16:05:31
Documents
15
Period of Report
2024-08-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d883504d8k.htm   iXBRL 8-K 28082
2 EX-10.1 d883504dex101.htm EX-10.1 78962
3 EX-10.2 d883504dex102.htm EX-10.2 37249
  Complete submission text file 0001193125-24-209907.txt   298733

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kpti-20240826.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20240826_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20240826_pre.xml EX-101.PRE 11259
17 EXTRACTED XBRL INSTANCE DOCUMENT d883504d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241263624
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)